– Conference Call Today at 4:30 p.m. ET
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include:


Third Quarter and Recent Highlights
“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow,” said Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer. “As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow. We are investing in field education to make earlier recognition of TA-TMA and timely treatment with YARTEMLEA part of everyday transplant care. We are also working to expand TA-TMA patient access through international regulatory approvals and named-patient programs. In the U.S., we are helping transplant centers understand YARTEMLEA’s reimbursement advantages, including additional Medicare inpatient payments under NTAP, effective October 1, and favorable Medicare outpatient reimbursement for 340B-acquired YARTEMLEA beginning January 1, 2027.
“We see YARTEMLEA not simply as a TA-TMA drug, but as an endothelial injury drug with broad therapeutic potential. YARTEMLEA revenues are funding our efforts to expand its indications, with clinical studies expected to begin soon in ARDS and TA-TMA prevention, and to initiate the Phase 2 clinical program for our long-acting MASP-2 inhibitor OMS1029. Together with expected zaltenibart-related milestone payments from Novo, these revenues are driving the rest of our pipeline forward: the OMS527 Phase 2 trial in cocaine use disorder planned to start early next year; the OncotoX-AML Phase 1b trial slated for late 2027; T-CAT, now in IND-enabling studies; and oral MASP-2 and MASP-3 inhibitors advancing toward the clinic. Across these first-in-class programs, as with YARTEMLEA, our objective remains to improve outcomes and save patients’ lives.”
Recent Developments
Financial Results
YARTEMLEA gross revenue was $41.8 million during the third quarter of 2026, an increase of $9.5 million, or 29.6%, from gross revenue of $32.2 million in the second quarter of 2026. Net revenue increased 26% to $35.9 million from $28.5 million in the second quarter. The third-quarter gross-to-net adjustment was 14.0%, compared to 11.5% in the second quarter. This increase in gross-to-net adjustment was driven by higher purchases by entities covered by the 340B Drug Pricing Program, consistent with our goals of increasing outpatient utilization of YARTEMLEA and expanding our customer base.
GAAP net loss for the third quarter of 2026 was $57.4 million, or $0.79 per share, including a non-cash loss of $62.0 million primarily related to mark-to-market adjustments of a derivative associated with our 2029 Notes. This compares with GAAP net income of $13.2 million, or $0.18 per share, for the second quarter, which included a non-cash gain of $11.4 million primarily related to the same mark-to-market adjustments.
Excluding these non-cash items, non-GAAP adjusted net income for the third quarter of 2026 was $4.7 million, or $0.06 per share, compared with $1.8 million, or $0.02 per share, for the second quarter.
At September 30, 2026, we had $95.3 million of cash and short-term investments. We generated positive operating cash flow of $13.3 million in the third quarter of 2026.
In June and July 2026, we entered into privately negotiated agreements with certain holders of the 2029 Notes under which we agreed to repurchase $30.5 million aggregate principal amount of the 2029 Notes for a total purchase price of $60.2 million, plus accrued and unpaid interest of $0.2 million. Both transactions closed in July 2026, leaving approximately $40.3 million aggregate principal amount of the 2029 Notes outstanding. In addition to eliminating approximately $8.6 million in future interest payment obligations, the repurchases reduced the aggregate number of shares issuable on conversion of the 2029 Notes by 4.9 million shares. Together with our repurchase of more than 843,000 shares of common stock at a volume-weighted average price of $11.70 per share during the first half of 2026, these transactions reduced the number of outstanding or potentially issuable shares by 5.8 million year to date.
Research and development and selling, general and administrative expenses totaled approximately $30.6 million in the third quarter, compared with $27.7 million in the second quarter. We reported operating income of $4.5 million for the third quarter compared with $0.1 million for the second quarter.
Interest and other income were $1.9 million for the third quarter of 2026, compared to $4.6 million during the second quarter of 2026. The $2.7 million decrease was primarily the result of a reimbursement from Novo for the transfer of zaltenibart inventory recorded in the second quarter.
Conference Call Details
Omeros’ management will host a conference call and webcast to discuss these financial results and to provide an update on business activities. The call will be held today at 1:30 p.m. Pacific Time; 4:30 p.m. Eastern Time.
To access the live webcast, register at https://events.q4inc.com/attendee/283590793 or visit Omeros’ website at https://investor.omeros.com/upcoming-events.
A replay of the call will be available online for 90 days at https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biotechnology company that discovers, develops, and commercializes first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on the treatment of complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead complement inhibitor YARTEMLEA® (narsoplimab-wuug), which targets the lectin pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients two years of age and older. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.
Under an asset purchase and licensing agreement, Novo acquired global rights to zaltenibart (formerly OMS906) and associated intellectual property and related assets. Zaltenibart is an inhibitor of MASP-3, the alternative pathway’s key activator, and is in clinical development for paroxysmal nocturnal hemoglobinuria (PNH) and other diseases mediated by the alternative pathway. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder. Development of OMS527 for this indication is fully funded by the National Institute on Drug Abuse. Omeros is also advancing a growing portfolio of novel recombinant antibodies targeting multidrug-resistant organisms and novel molecular and cellular therapeutic programs for oncology. For more information about Omeros and its programs, visit www.omeros.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “should,” “slate,” “target,” “will,” “would,” and similar expressions and variations thereof. Forward-looking statements, including statements regarding the anticipated therapeutic benefits of drug candidates within our development pipeline, plans and expectations regarding the commercial launch of YARTEMLEA® in the U.S., our expectations regarding the utility of the NTAP, our expectations regarding development of zaltenibart, our ability to consummate licensing, partnering or other transactions and the benefits, if any, we would receive from any such transactions, expectations regarding the sufficiency and availability of our capital resources to fund current and planned operations, including the commercialization of YARTEMLEA, are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unfavorable or unexpected regulatory conclusions or interpretations related to the clinical data, external registry data, statistical analyses or other information and data included in our marketing authorization application or our inability to respond satisfactorily to information requests during regulatory review, unanticipated or unexpected outcomes or requirements of regulatory processes in relevant jurisdictions, our financial condition and results of operations, including our ability to raise additional capital for our operations or complete other transactions on favorable terms or at all, regulatory processes and oversight, challenges associated with manufacture or supply of our products to support clinical trials, regulatory inspections and/or commercial sale following any marketing approval, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties, and other factors described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026 and in our subsequently filed Quarterly Reports on Form 10-Q. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Non-GAAP Financial Measures
This press release includes financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). A non-GAAP financial measure is generally defined as one that purports to measure historical or future financial position, results of operations or cash flows but excludes or includes amounts that would not be included in most GAAP measures. We define non-GAAP adjusted net income (loss) as GAAP net income (loss) adjusted to exclude the non-cash remeasurement of the fair value of financial instruments. We believe non-GAAP adjusted net income (loss) to be a more accurate measure in evaluating the Company’s performance because it excludes the fluctuations in the fair value of Omeros’ embedded derivatives. This is not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with Omeros’ financial statements prepared in accordance with GAAP. These non-GAAP measures differ from GAAP measures with the same captions, may be different from non-GAAP financial measures with the same or similar captions that are used by other companies, and do not reflect a comprehensive system of accounting.
OMEROS CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (In thousands, except share and per share data) | ||||||||||||||||
|
| Three Months Ended |
| Nine Months Ended | ||||||||||||
|
| September 30, |
| September 30, | ||||||||||||
|
| 2026 |
| 2025 |
| 2026 |
| 2025 | ||||||||
Product sales, net |
| $ | 35,934 |
|
| $ | — |
|
| $ | 74,356 |
|
| $ | — |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Costs and expenses: |
|
|
|
|
|
|
|
|
|
| ||||||
Cost of product sales |
|
| 826 |
|
|
| — |
|
|
| 2,211 |
|
|
| — |
|
Research and development |
|
| 16,060 |
|
|
| 15,995 |
|
|
| 43,216 |
|
|
| 61,850 |
|
Selling, general and administrative |
|
| 14,547 |
|
|
| 10,397 |
|
|
| 41,775 |
|
|
| 31,865 |
|
Total costs and expenses |
|
| 31,433 |
|
|
| 26,392 |
|
|
| 87,202 |
|
|
| 93,715 |
|
Income (loss) from operations |
|
| 4,501 |
|
|
| (26,392 | ) |
|
| (12,846 | ) |
|
| (93,715 | ) |
Interest and other income |
|
| 1,867 |
|
|
| 616 |
|
|
| 7,968 |
|
|
| 2,979 |
|
Interest expense, net of remeasurement adjustments and other |
|
| (6,222 | ) |
|
| 13,355 |
|
|
| (19,701 | ) |
|
| 9,686 |
|
Net gain (loss) on change in fair value of financial instruments |
|
| (62,020 | ) |
|
| (8,822 | ) |
|
| 22,573 |
|
|
| (680 | ) |
Loss on early extinguishment of 2029 Notes |
|
| (1,905 | ) |
|
| — |
|
|
| (3,801 | ) |
|
| — |
|
Loss on early extinguishment of 2026 Notes |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (2,968 | ) |
Loss from continuing operations before income tax expense |
|
| (63,779 | ) |
|
| (21,243 | ) |
|
| (5,807 | ) |
|
| (84,698 | ) |
Income tax expense |
|
| (46 | ) |
|
| — |
|
|
| (132 | ) |
|
| — |
|
Net loss from continuing operations |
|
| (63,825 | ) |
|
| (21,243 | ) |
|
| (5,939 | ) |
|
| (84,698 | ) |
Net income (loss) from discontinued operations, net of tax |
|
| 6,469 |
|
|
| (9,674 | ) |
|
| 17,875 |
|
|
| (5,103 | ) |
Net income (loss) |
| $ | (57,356 | ) |
| $ | (30,917 | ) |
| $ | 11,936 |
|
| $ | (89,801 | ) |
|
|
|
|
|
|
|
|
| ||||||||
Basic net income (loss) per share: |
|
|
|
|
|
|
|
| ||||||||
Net loss from continuing operations |
| $ | (0.88 | ) |
| $ | (0.32 | ) |
| $ | (0.09 | ) |
| $ | (1.39 | ) |
Net income (loss) from discontinued operations |
|
| 0.09 |
|
|
| (0.15 | ) |
|
| 0.25 |
|
|
| (0.08 | ) |
Net income (loss) |
| $ | (0.79 | ) |
| $ | (0.47 | ) |
| $ | 0.16 |
|
| $ | (1.47 | ) |
|
|
|
|
|
|
|
|
| ||||||||
Diluted net income (loss) per share: |
|
|
|
|
|
|
|
| ||||||||
Net loss from continuing operations |
| $ | (0.87 | ) |
| $ | (0.32 | ) |
| $ | (0.07 | ) |
| $ | (1.39 | ) |
Net income (loss) from discontinued operations |
|
| 0.09 |
|
|
| (0.15 | ) |
|
| 0.20 |
|
|
| (0.08 | ) |
Net income (loss) |
| $ | (0.79 | ) |
| $ | (0.47 | ) |
| $ | 0.13 |
|
| $ | (1.47 | ) |
|
|
|
|
|
|
|
|
| ||||||||
Weighted-average shares used in per share computation: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Basic |
|
| 72,981,654 |
|
|
| 66,263,992 |
|
|
| 72,349,533 |
|
|
| 61,049,886 |
|
Diluted |
|
| 72,981,654 |
|
|
| 66,263,992 |
|
|
| 88,864,266 |
|
|
| 61,049,886 |
|
OMEROS CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) | ||||||||
|
| September 30, |
| December 31, | ||||
|
| 2026 |
| 2025 | ||||
Assets |
|
|
|
| ||||
Current assets: |
|
|
|
| ||||
Cash and cash equivalents |
| $ | 5,070 |
|
| $ | 9,660 |
|
Short-term investments |
|
| 90,180 |
|
|
| 162,144 |
|
OMIDRIA contract royalty asset, short-term |
|
| 25,730 |
|
|
| 25,351 |
|
Receivables |
|
| 23,096 |
|
|
| 10,917 |
|
Inventory |
|
| 66 |
|
|
| — |
|
Prepaid expense and other assets |
|
| 6,751 |
|
|
| 7,595 |
|
Total current assets |
|
| 150,893 |
|
|
| 215,667 |
|
OMIDRIA contract royalty asset |
|
| 87,897 |
|
|
| 96,435 |
|
Right of use assets |
|
| 7,004 |
|
|
| 10,708 |
|
Property and equipment, net |
|
| 1,247 |
|
|
| 1,768 |
|
Restricted investments |
|
| 1,054 |
|
|
| 1,054 |
|
Total assets |
| $ | 248,095 |
|
| $ | 325,632 |
|
|
|
|
|
| ||||
Liabilities and shareholders’ deficit |
|
|
|
|
|
| ||
Current liabilities: |
|
|
|
|
|
| ||
Accounts payable |
| $ | 4,902 |
|
| $ | 4,764 |
|
Accrued expenses |
|
| 32,532 |
|
|
| 29,388 |
|
OMIDRIA royalty obligation |
|
| 22,338 |
|
|
| 20,547 |
|
2026 Notes, net |
|
| — |
|
|
| 17,063 |
|
Lease liabilities |
|
| 6,798 |
|
|
| 6,300 |
|
Total current liabilities |
|
| 66,570 |
|
|
| 78,062 |
|
OMIDRIA royalty obligation, non-current |
|
| 130,624 |
|
|
| 147,319 |
|
2029 Notes, non-current, net |
|
| 31,891 |
|
|
| 51,364 |
|
2029 Notes embedded derivative, non-current |
|
| 101,136 |
|
|
| 157,171 |
|
Lease liabilities, non-current |
|
| 2,145 |
|
|
| 7,245 |
|
Other accrued liabilities, non-current |
|
| 5,702 |
|
|
| 5,702 |
|
Shareholders’ deficit: |
|
|
|
|
|
| ||
Common stock and additional paid-in capital |
|
| 811,786 |
|
|
| 792,464 |
|
Accumulated deficit |
|
| (901,759 | ) |
|
| (913,695 | ) |
Total shareholders’ deficit |
|
| (89,973 | ) |
|
| (121,231 | ) |
Total liabilities and shareholders’ deficit |
| $ | 248,095 |
|
| $ | 325,632 |
|
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
IR@omeros.com
| 51 min | |
| 1 hour | |
| 2 hours | |
| Nov-11 | |
| Nov-10 | |
| Oct-16 | |
| Oct-16 | |
| Oct-16 | |
| Oct-16 | |
| Oct-16 | |
| Sep-22 | |
| Aug-12 | |
| Aug-12 | |
| Aug-12 | |
| Aug-10 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite